Proteome-genome complexity as a metric of refractory disease.
Treatment decisions for refractory diseases are frequently challenging because the benefits of disease-free survival and relief of symptoms must be balanced against the severity and frequency of side effects. A precise measure of disease resistance would therefore be valuable when assessing possible treatment strategies. In recent years there has been much interest in the modeling of proteomes and genomes as a means of identifying major pathways of disease causation. We suggest that these analyses may offer the additional benefit of quantifying refractory.